GERN Geron Corporation - Common Stock
NASDAQ · Biotechnology · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 5, 2026GERN Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
GERN Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
| Fecha ex-dividendo | División | Tipo |
|---|---|---|
| 22 de julio de 2014 | 529-for-500 | Adelante |
Acerca de Geron Corporation - Common Stock Descripción general de la empresa de Wikipedia
Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
Company information
Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. The company was incorporated in 1990 and began doing business in 1992. John A. Scarlett was appointed CEO in 2011.
The company's Scientific and Clinical Advisory Board has included Nobel laureates James Watson, Gunter Blobel, and Carol Greider, and Leonard Hayflick, known for discovering that human cells divide for a limited number of times in vitro (called the Hayflick limit).
In 2017, Geron staff received the highest median pay in California, at $500,250.
Drug candidates
Cancer therapies
Geron Corporation has sponsored human clinical trials of several potential anti-cancer products.
Imetelstat (GRN163L) is a drug that targets telomerase. In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. Similarly, GRN163L inhibited the in vitro clonogenic growth of CD138neg Multiple Myeloma Cancer Stem Cells isolated from the bone marrow aspirates of patients with multiple myeloma. On November 3, 2014, the FDA removed the full clinical hold on imetelstat and declared the company's clinical development plan as acceptable. In 2014, Geron licensed imetelstat to Janssen Biotech. In 2017, imetelstat was granted fast track status by the FDA for certain patients with myelodysplastic syndrome. In 2018, Janssen Biotech returned the rights to imetelstat to Geron. Imetelstat is currently in two Phase 3 trials: NCT02598661, a study of the drug's ability to reduce the transfusion requirements of patients with myelodysplastic syndrome (MDS), and NCT04576156, an investigation of the drug's effect on the overall survival of patients with myelofibrosis.
A trial of GRNVAC1, a telomerase vaccine being used on patients with prostate cancer was carried out at Duke University. Geron's progress with telomerase vaccines attracted a modest monetary investment in 2005 from Merck.
GRN1005, an LRP-directed conjugate of paclitaxel, was in phase II clinical trials for brain cancer but discontinued based on preliminary results in 2012.
Telomerase activation
In addition to testing drug candidates that exploit cancer cell's dependence on telomerase, Geron is researching the possible applications of activating the enzyme in normal cells to delay cellular senescence. The company is in the early stages of developing a telomerase based treatment for HIV called TAT0002, which is the saponin cycloastragenol in Chinese herb Astragalus propinquus. Geron has granted a license to Telomerase Activation Sciences to sell TA-65, the telomerase activator agent also derived from astragalus. In October 2010 Intertek/AAC Labs, an ISO 17025 internationally recognized lab, found the largest component of TA-65 to be cycloastragenol.
Geron originally investigated telomerase as a means of understanding and modifying human aging. However, Geron has ceased aging research of any kind.
Stem cell therapies
On January 23, 2009, Geron received FDA approval to begin Phase I testing of GRNOPC1 in humans. GRNOPC1 is an embryonic stem cell based drug that is designed to treat specific forms of spinal cord injury through remyelination of damaged axons. This trial does not involve direct use of stem cells however, as GRNOPC1 is composed of oligodendrocyte progenitor cells derived from embryonic stem cell lines. Studies have shown significant restoration of mobility in animals with spinal injuries that received cells.
Geron also has several other embryonic stem cell treatments that are still in the preclinical phase, including GRNCM1, a treatment for heart disease, and GRNIC1, a treatment for diabetes. In tests with diabetic mice, 80% of the mice given GRNIC1 were still alive in 50 days while the entire control group, which was given no treatment, perished.
Geron sold its human stem cell research assets to Asterias in 2013.
GRNOPC1
As of October 2010 and November 2010, one of Geron's most highly publicized trial therapy products has been GRNOPC1, a stem cell therapy designed to heal severe spinal cord injuries. The cells in the GRNOPC1 therapy have been coaxed into becoming early myelinated glial cells, a type of cell that insulates nerve cells. For every GRNOPC1 cell that is injected in the patient, they become six to ten cells in a few months.
In October 2011 updated results on four patients were released. The trial was discontinued in Nov 2011.
In early 2013 BioTime, whose CEO at the time was Geron founder Michael D. West, acquired 400 patents and other intellectual property related to embryonic stem cells from Geron and later went on to restart the trial.
Patent issues
Geron Corporation initially held exclusive rights to three cell types derived from embryonic stem cells, as the result of paying for the research originally conducted by Dr. James Thomson at the University of Wisconsin–Madison. The patents on the other three cell types are owned by the Wisconsin Alumni Research Foundation (WARF). WARF and Geron did not charge academics to study human stem cells but did charge commercial users. In 2001 WARF came under public pressure to widen access to human stem-cell technology, and they launched legal action against Geron Corporation to recover some of the previously sold rights. The two sides agreed that Geron would keep the rights to only three cell types.
In October 2006, a legal challenge was mounted to overturn these patents by The Foundation for Taxpayer and Consumer Rights and the non-profit patent-watchdog Public Patent Foundation. They contended that two of the patents granted to WARF are invalid because they cover a technique published in 1992 for which a patent had already been granted to an Australian researcher. Another part of the challenge came from the molecular biologist Jeanne Loring who stated that University of Wisconsin–Madison stem cell pioneer James Thomson's techniques (currently patents held by WARF) are rendered obvious by a 1990 paper and two textbooks. The outcome of this legal challenge was particularly relevant to the Geron Corporation as it can only license patents that are upheld. The patents were ultimately upheld when the reexamination concluded in 2008.
As an interim measure, on January 23, 2007, WARF relaxed the stem cell patents, allowing industry-sponsored research at academic and non-profit institutions without a license. WARF will allow easier and simpler cost free cell transfers among researchers and would not require a license or agreement from California's taxpayer-funded stem cell research program.
Politics
As a participant in the then-controversial stem cell and cloning area, Geron Corporation was asked to testify about its technology before the U.S. Congress. In 2001, when Congress was attempting to ban all forms of cloning, then Geron CEO Thomas Okarma spoke before Congress to preserve cloning for therapeutic purposes.
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | GERN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/E | -0.0promedio 5A ≈-8.0 | ≈-8.0 | · | · | |
| P/S | 0.0promedio 5A ≈1359.4 | ≈1359.4 | 8.0 | Infravalorado | |
| P/C (MRQ) | 0.0promedio 5A ≈6.2 | ≈6.2 | 2.7 | Infravalorado | |
| EV / EBITDA | -0.6promedio 5A ≈-8.4 | ≈-8.4 | · | · | |
| Price / Cash Flow (Precio / Flujo de Caja) | -0.0promedio 5A ≈-7.2 | ≈-7.2 | · | · | |
| EV / Revenue (EV / Ingresos) | 0.3promedio 5A ≈1370.0 | ≈1370.0 | · | · | |
| Price / Tangible Book (Precio / Valor Contable Tangible) | 0.0promedio 5A ≈6.2 | ≈6.2 | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | GERN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| ROA | -14.3%promedio 5A ≈-45.5% | ≈-45.5% | -33.0% | De primer nivel | |
| ROE | -34.4%promedio 5A ≈-79.6% | ≈-79.6% | -39.4% | En línea | |
| ROIC | -19.9% | · | -34.7% | De primer nivel |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | GERN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Deuda / Patrimonio (MRQ) | 0.5promedio 5A ≈0.5 | ≈0.5 | · | · | |
| Ratio corriente (MRQ) | 6.9promedio 5A ≈4.0 | ≈4.0 | 8.9 | Baja liquidez | |
| Quick Ratio (Ratio Rápido) | 1.0promedio 5A ≈0.9 | ≈0.9 | 7.6 | Baja liquidez | |
| Deuda a Largo Plazo / Patrimonio (MRQ) | 0.5promedio 5A ≈0.4 | ≈0.4 | · | · |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
| Métrica | Tendencia a 5 años | GERN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue YoY (Ingresos interanuales) | -60.2%promedio 5A ≈111.0% | ≈111.0% | · | · | |
| Revenue CAGR 3Y (Ingresos CAGR 3A) | -2.1% | · | · | · |
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | GERN | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Revenue / Employee (Ingresos / Empleado) | ≈$918.60 | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de junio de 2026 | Ago 6, 2026 | $-0.02 | $-0.01 | — |
| 31 de marzo de 2026 | $-0.01 | $-0.02 | 52.6% | |
| 31 de diciembre de 2025 | $-0.02 | $-0.03 | 38.1% | |
| 30 de septiembre de 2025 | $-0.03 | $-0.03 | 11.0% | |
| 30 de junio de 2025 | $-0.02 | $-0.03 | 35.7% | |
| 31 de marzo de 2025 | $-0.03 | $-0.04 | 22.3% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $237.0K | $596.0K | $1M | $253.0K | $460.0K | $1M | $1M | $6M | $36M | $1M | |
| SG&A Expense | $159M | $146M | $69M | $44M | $30M | $26M | $21M | $19M | $19M | $19M | $18M | $17M | |
| Operating Expenses | $252M | $251M | $194M | $139M | $115M | $77M | $73M | $32M | $30M | $37M | $37M | $37M | |
| Operating Income | $-69M | $-174M | $-194M | $-139M | $-114M | $-77M | $-73M | $-31M | $-29M | $-31M | $-559.0K | $-36M | |
| Interest Expense | · | $19M | $8M | $7M | $4M | $760.0K | · | · | · | · | · | · | |
| Interest Income | $18M | $20M | $18M | $3M | $527.0K | $2M | $4M | $3M | · | · | · | · | |
| Other Non-op | $-375.0K | $-236.0K | $-23.0K | $1M | $1M | $168.0K | $-69.0K | $-114.0K | · | · | · | · | |
| Pretax Income | $-83M | $-175M | $-182M | $-142M | · | · | · | · | · | · | · | · | |
| Income Tax | $75.0K | $449.0K | $22.0K | · | · | · | · | · | · | · | · | · | |
| Net Income | $-84M | $-175M | $-184M | $-142M | $-116M | $-76M | $-69M | $-27M | $-28M | $-30M | $46.0K | $-36M | |
| EPS (Basic) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 | |
| EPS (Diluted) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 | |
| Shares (Basic) | 666,662,989 | 646,033,247 | 570,645,405 | 380,784,846 | 327,631,814 | 271,460,265 | · | · | 159,224,986 | 159,045,644 | 158,036,162 | 153,540,341 | |
| Shares (Diluted) | 666,662,989 | 646,033,247 | 570,645,405 | 380,784,846 | 327,631,814 | 271,460,265 | · | · | 159,224,986 | 159,045,644 | 162,663,894 | 153,540,341 | |
| EBITDA | $-69M | $-174M | $-194M | $-139M | $-114M | $-77M | $-73M | $-31M | $-29M | $-31M | $-559.0K | $-36M |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $78M | $79M | $70M | $57M | $35M | $10M | $14M | $11M | $16M | $13M | $21M | $43M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $78M | $102M | $93M | $109M | |
| Receivables | $37M | $36M | · | · | · | · | · | · | · | · | · | · | |
| Inventory | $117M | $39M | · | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $5M | $5M | $5M | $4M | $1M | $2M | $1M | $1M | $580.0K | $524.0K | $647.0K | $736.0K | |
| Current Assets | $520M | $491M | $341M | $180M | $187M | $200M | $142M | $166M | $96M | $116M | $116M | $153M | |
| PP&E (Net) | $884.0K | $1M | $1M | $793.0K | $650.0K | $658.0K | $408.0K | $59.0K | $102.0K | $183.0K | $207.0K | $173.0K | |
| PP&E (Gross) | $3M | $3M | $2M | $2M | $1M | $1M | $1M | $838.0K | $822.0K | $1M | $1M | $1M | |
| Accum. Depreciation | $2M | $2M | $1M | $896.0K | $650.0K | $613.0K | $843.0K | $779.0K | $720.0K | $1M | $1M | $1M | |
| Other Non-current Assets | · | · | · | · | · | · | · | $585.0K | · | · | · | · | |
| Total Assets | $571M | $594M | $394M | $191M | $226M | $271M | $166M | $185M | $110M | $130M | $149M | $173M | |
| Accounts Payable | $11M | $9M | $6M | $10M | $7M | $7M | $1M | $982.0K | $503.0K | $225.0K | $160.0K | $1M | |
| Accrued Liabilities | $51M | $36M | $40M | $33M | $30M | $15M | $8M | $1M | $926.0K | $1M | $1M | $2M | |
| Current Liabilities | $112M | $88M | $108M | $77M | $46M | $31M | $28M | $8M | $7M | $8M | $7M | $42M | |
| Capital Leases | $1M | $2M | $3M | $4M | $4M | $5M | $2M | · | · | · | · | · | |
| Total Liabilities | $345M | $313M | $146M | $111M | $100M | $60M | $30M | · | · | · | · | · | |
| Long-term Debt | · | · | $82M | $51M | · | · | · | · | · | · | · | · | |
| Total Debt | $120M | $118M | $82M | $51M | $50M | $24M | · | · | · | · | · | · | |
| Common Stock | $640.0K | $606.0K | $545.0K | $390.0K | $324.0K | $310.0K | $200.0K | $186.0K | $160.0K | $159.0K | $159.0K | $157.0K | |
| Retained Earnings | $-1.86B | $-1.77B | $-1.60B | $-1.41B | $-1.27B | $-1.16B | $-1.08B | $-1.01B | $-986M | $-958M | $-928M | $-928M | |
| AOCI | $269.0K | $261.0K | $185.0K | $-219.0K | $-173.0K | $78.0K | $132.0K | $-183.0K | $-207.0K | $-53.0K | $-213.0K | $-84.0K | |
| Stockholders' Equity | $226M | $280M | $248M | $80M | $126M | $211M | $135M | $178M | $104M | $122M | $142M | $131M | |
| Liabilities + Equity | $571M | $594M | $394M | $191M | $226M | $271M | $166M | $185M | $110M | $130M | $149M | $173M | |
| Shares Outstanding | 639,856 | 606,388,000 | 544,912,215 | 390,262,524 | 323,731,591 | 310,566,853 | 199,814,581 | 186,392,682 | 159,877,239 | 159,158,636 | 158,781,359 | 157,429,871 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $474.0K | $546.0K | $442.0K | $288.0K | $215.0K | $158.0K | $64.0K | · | · | · | · | · | |
| Stock-based Comp | $27M | $31M | $19M | $8M | $8M | $7M | $6M | $6M | $8M | $8M | $8M | $8M | |
| Restructuring | $17M | $0 | $0 | · | · | · | · | · | · | · | $1M | · | |
| Operating Cash Flow | $-111M | $-219M | $-168M | $-127M | $-96M | $-67M | $-44M | $-21M | $-21M | $-18M | $-24M | $9M | |
| CapEx | · | $680.0K | $830.0K | $431.0K | $207.0K | $401.0K | $413.0K | $16.0K | · | $57.0K | $90.0K | $131.0K | |
| Investing Cash Flow | $107M | $-106M | $-180M | $62M | $72M | $-105M | $27M | $-78M | $23M | $9M | $73.0K | · | |
| Debt Issued | $0 | $121M | $30M | · | $25M | $24M | · | · | · | · | · | · | |
| Net Debt Issued | $0 | $35M | $30M | · | $25M | $24M | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $20M | $4M | $19M | $86M | $1M | $1M | $3M | $98M | |
| Net Stock Activity | · | · | · | · | $20M | $4M | $19M | $86M | $1M | $1M | $3M | $98M | |
| Dividends Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | |
| Financing Cash Flow | $2M | $334M | $362M | $87M | $49M | $168M | $19M | $93M | $1M | $1M | $3M | · | |
| Net Change in Cash | $-1M | $10M | $14M | $22M | $25M | · | · | · | $4M | $-8M | $-22M | · | |
| Free Cash Flow | · | $-219M | $-169M | $-128M | $-96M | $-67M | $-44M | $-21M | · | $-18M | $-24M | $9M | |
| Levered FCF | · | $-238M | · | · | · | · | · | · | · | · | · | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | -81832.9% | -23246.6% | -8183.7% | -30400.4% | -15762.0% | -2914.9% | -2746.9% | -497.3% | -1.5% | · | |
| Net Margin | · | · | -77690.7% | -23808.9% | -8335.4% | -29888.1% | -14901.7% | -2534.4% | -2621.2% | -479.3% | 0.13% | · | |
| EBITDA Margin | · | · | -81832.9% | -23246.6% | -8183.7% | -30400.4% | -15762.0% | -2914.9% | -2746.9% | -497.3% | -1.5% | · | |
| ROA | -14.3% | -35.3% | -63.0% | -68.1% | -46.8% | -34.7% | -39.1% | -18.3% | -23.2% | -21.2% | 0.03% | -29.7% | |
| ROE | -34.4% | -61.0% | -68.4% | -150.8% | -83.5% | -34.1% | -47.7% | -15.0% | -24.7% | -22.3% | 0.03% | -37.5% | |
| ROIC | -19.9% | -43.7% | · | · | · | · | · | · | · | · | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | 5.6 | 3.2 | 2.4 | 4.1 | 6.5 | 5.0 | 22.0 | 14.7 | 14.8 | 17.5 | 3.7 | |
| Quick Ratio | 1.0 | 1.3 | 0.6 | 0.7 | 0.8 | 0.3 | 0.5 | 1.4 | 14.5 | 14.6 | 17.1 | 3.6 | |
| Debt / Equity | 0.5 | 0.4 | 0.3 | 0.6 | 0.4 | 0.1 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 0.4 | 0.1 | 0.4 | 0.4 | 0.1 | · | · | · | · | · | · | |
| Interest Coverage | · | -9.4 | -23.3 | -20.1 | -30.5 | -101.2 | · | · | · | · | · | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.35 | $0.46 | $0.46 | $0.20 | $0.39 | $0.68 | $0.68 | $0.95 | $0.65 | $0.77 | $0.90 | $0.83 | |
| Revenue / Share | · | · | $0.00 | $0.00 | · | · | · | · | $0.01 | $0.04 | $0.22 | · | |
| Cash Flow / Share | $-0.17 | $-0.34 | $-0.29 | $-0.33 | · | · | · | · | $-0.13 | $-0.12 | $-0.15 | · | |
| Cash / Share | $0.12 | $0.13 | $0.13 | $0.15 | $0.11 | $0.03 | $0.07 | $0.06 | $0.10 | $0.08 | $0.13 | $0.27 | |
| EPS (TTM) | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 | $-0.28 | · | · | $-0.18 | $-0.19 | $0.00 | $-0.23 |
Tasas de Crecimiento
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | -60.2% | -57.2% | 450.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | · | · | -2.1% | · | · | · | · | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $164M | $30M | $237.0K | $596.0K | $1M | $253.0K | $460.0K | $1M | $1M | $6M | $36M | $1M | |
| Net Income TTM | $-84M | $-175M | $-184M | $-142M | $-116M | $-76M | $-69M | $-27M | $-28M | $-30M | $46.0K | $-36M | |
| Market Cap | $845M | $2.15B | $1.15B | $944M | $395M | $494M | $272M | $186M | $288M | $329M | $769M | $512M | |
| Enterprise Value | $887M | $2.19B | $1.16B | $939M | $410M | $508M | · | · | · | · | · | · | |
| P/E | -10.2 | -13.1 | -6.6 | -6.5 | -3.5 | -5.7 | · | · | -10.0 | -10.9 | · | -14.1 | |
| P/S | 5.1 | 72.5 | 4851.3 | 1584.6 | 283.5 | 1951.8 | 590.8 | 174.9 | 270.2 | 53.5 | 21.1 | 443.8 | |
| P/B | 3.7 | 7.7 | 4.6 | 11.8 | 3.1 | 2.3 | 2.0 | 1.0 | 2.8 | 2.7 | 5.4 | 3.9 | |
| P / Tangible Book | 3.7 | 7.7 | 4.6 | 11.8 | 3.1 | 2.3 | · | · | · | · | · | · | |
| P / Cash Flow | -7.6 | -9.8 | -6.9 | -7.4 | -4.1 | -7.4 | -6.2 | -8.9 | -14.0 | -17.9 | -31.8 | 54.7 | |
| P / FCF | · | -9.8 | -6.8 | -7.4 | -4.1 | -7.4 | -6.1 | -8.9 | · | -17.9 | -31.6 | 55.5 | |
| EV / EBITDA | -12.9 | -12.6 | -6.0 | -6.8 | -3.6 | -6.6 | · | · | · | · | · | · | |
| EV / FCF | · | -10.0 | -6.9 | -7.3 | -4.3 | -7.6 | · | · | · | · | · | · | |
| EV / Revenue | 5.4 | 73.8 | 4901.6 | 1575.1 | 294.3 | 2007.6 | · | · | · | · | · | · | |
| Dividend Yield | · | · | · | · | · | · | · | · | · | · | 0.00% | 0.00% | |
| Earnings Yield | -9.8% | -7.6% | -15.2% | -15.3% | -28.7% | -17.6% | · | · | -10.0% | -9.2% | 0.00% | -7.1% | |
| Payout Ratio | · | · | · | · | · | · | · | · | · | · | 0.00% | 0.00% | |
| Annual Payout | · | · | · | · | · | · | · | · | · | · | $0 | $0 |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $52M | · | $47M | $49M | $40M | · | $28M | $882.0K | $304.0K | $164.0K | $29.0K | $21.0K | $297.0K | $73.0K | $123.0K | |
| SG&A Expense | $39M | $35M | $42M | $39M | $39M | $40M | $43M | $36M | $39M | $27M | $18M | $16M | $13M | $16M | $7M | $7M | |
| Operating Expenses | $70M | $52M | $74M | $61M | $61M | $56M | $68M | $56M | $70M | $56M | $48M | $52M | $40M | $40M | $28M | $29M | |
| Operating Income | $-12M | $158.0K | $-26M | $-14M | $-12M | $-17M | $-20M | $-28M | $-69M | $-56M | $-48M | $-52M | $-40M | $-40M | $-28M | $-29M | |
| Interest Expense | · | · | · | · | · | · | · | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $1M | |
| Interest Income | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $4M | $852.0K | $330.0K | $112.0K | |
| Other Non-op | $-9.0K | $-74.0K | $-70.0K | $-161.0K | $-61.0K | $-83.0K | $-48.0K | $-63.0K | $-63.0K | $-62.0K | $-92.0K | $-11.0K | $39.0K | $-138.0K | $1M | $-56.0K | |
| Net Income | $-17M | $-4M | $-29M | $-18M | $-16M | $-20M | $-25M | $-26M | $-67M | $-55M | $-45M | $-49M | $-38M | $-41M | $-28M | $-30M | |
| EPS (Basic) | $-0.02 | $-0.01 | $-0.05 | $-0.03 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.10 | $-0.09 | $-0.08 | $-0.09 | $-0.07 | $-0.10 | $-0.07 | $-0.09 | |
| EPS (Diluted) | $-0.02 | $-0.01 | $-0.05 | $-0.03 | $-0.02 | $-0.03 | $-0.04 | $-0.04 | $-0.10 | $-0.09 | $-0.08 | $-0.09 | $-0.07 | $-0.10 | $-0.07 | $-0.09 | |
| Shares (Basic) | 670,696 | 669,375 | · | 667,101,756 | 666,170 | 665,905 | · | 662,158,182 | 653,904,978 | 603,493,451 | 579,508,305 | 547,280,946 | 544,459,004 | 405,237,474 | 403,868,713 | 332,066,889 | |
| Shares (Diluted) | 670,696 | 669,375 | · | 667,101,756 | 666,170 | 665,905 | · | 662,158,182 | 653,904,978 | 603,493,451 | 579,508,305 | 547,280,946 | 544,459,004 | 405,237,474 | 403,868,713 | 332,066,889 | |
| EBITDA | $-12M | $158.0K | · | $-14M | $-12M | $-17M | · | $-28M | $-69M | $-56M | $-48M | $-52M | $-40M | $-40M | $-28M | $-29M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63M | $69M | $78M | $78M | $78M | $84M | $79M | $60M | $117M | $190M | $31M | $57M | $113M | $61M | $76M | $31M | |
| Receivables | $52M | $42M | $37M | $35M | $37M | $31M | $36M | $28M | $874.0K | · | · | · | · | · | · | · | |
| Inventory | $124M | $133M | $117M | $95M | $69M | $56M | $39M | $20M | $774.0K | · | · | · | · | · | · | · | |
| Prepaid Expense | $6M | $7M | $5M | $7M | $7M | $7M | $5M | $6M | $6M | $6M | $6M | $4M | $4M | $5M | $3M | $4M | |
| Current Assets | $486M | $499M | $520M | $522M | $506M | $496M | $491M | $398M | $373M | $452M | $335M | $377M | $387M | $222M | $227M | $176M | |
| PP&E (Net) | $1M | $1M | $884.0K | $973.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $733.0K | $641.0K | $643.0K | |
| PP&E (Gross) | · | · | $3M | · | · | · | $3M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $2M | · | · | · | $2M | · | · | · | · | · | · | · | · | · | |
| Total Assets | $519M | $534M | $571M | $567M | $555M | $562M | $594M | $445M | $449M | $482M | $413M | $415M | $425M | $233M | $238M | $198M | |
| Accounts Payable | $9M | $13M | $11M | $11M | $8M | $8M | $9M | $14M | $6M | $10M | $14M | $8M | $3M | $8M | $5M | $6M | |
| Accrued Liabilities | $31M | $31M | $51M | $40M | $26M | $29M | $36M | $36M | $39M | $34M | $42M | $45M | $35M | $53M | $31M | $36M | |
| Current Liabilities | $70M | $74M | $112M | $88M | $64M | $63M | $88M | $138M | $104M | $123M | $89M | $73M | $44M | $83M | $47M | $47M | |
| Capital Leases | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | |
| Total Liabilities | $300M | $305M | $345M | · | · | · | $313M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | · | · | · | $84M | $83M | $83M | $52M | $52M | $51M | $51M | $50M | · | |
| Total Debt | $120M | $120M | · | $119M | $119M | $119M | · | $84M | $83M | $83M | $52M | $52M | $51M | $51M | $50M | $50M | |
| Common Stock | $642.0K | $641.0K | $640.0K | $638.0K | $638.0K | $637.0K | $606.0K | $603.0K | $601.0K | $591.0K | $542.0K | $522.0K | $509.0K | $382.0K | $378.0K | $324.0K | |
| Retained Earnings | $-1.88B | $-1.86B | $-1.86B | $-1.83B | $-1.81B | $-1.79B | $-1.77B | $-1.75B | $-1.72B | $-1.65B | $-1.55B | $-1.50B | $-1.45B | $-1.37B | $-1.33B | $-1.30B | |
| AOCI | $-339.0K | $-191.0K | $269.0K | $408.0K | $117.0K | $304.0K | $261.0K | $1M | $-537.0K | $-273.0K | $-950.0K | $-945.0K | $-160.0K | $-620.0K | $-782.0K | $-711.0K | |
| Stockholders' Equity | $219M | $229M | $226M | $249M | $260M | $268M | $280M | $292M | $307M | $345M | $291M | $298M | $326M | $108M | $142M | $97M | |
| Liabilities + Equity | $519M | $534M | $571M | $567M | $555M | $562M | $594M | $445M | $449M | $482M | $413M | $415M | $425M | $233M | $238M | $198M | |
| Shares Outstanding | 642,470 | 641,033,000 | 639,856,222 | 638,355,275 | 637,849,739 | 636,917,758 | 606,387,666 | 603,102,073 | 601,048,108 | 591,163,808 | 542,479,666 | 521,942,104 | 508,731,846 | 381,214,326 | 377,664,759 | 323,736,875 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $136.0K | $134.0K | $87.0K | $128.0K | $128.0K | $131.0K | $142.0K | $31.0K | $262.0K | $111.0K | $108.0K | $121.0K | $99.0K | $79.0K | $72.0K | $57.0K | |
| Stock-based Comp | $5M | $5M | $6M | $7M | $7M | $7M | $7M | $7M | $13M | $5M | $7M | $4M | $3M | $2M | $2M | $2M | |
| Restructuring | $-157.0K | $-394.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-16M | $-63M | $-22M | $-14M | $-27M | $-48M | $-44M | $-59M | $-53M | $-62M | $-51M | $-30M | $-46M | $-30M | $-29M | $-34M | |
| CapEx | · | · | · | · | · | · | · | $0 | $206.0K | $615.0K | $192.0K | $202.0K | $372.0K | $171.0K | $70.0K | $50.0K | |
| Investing Cash Flow | $8M | $52M | $21M | $13M | $20M | $52M | $-104M | $-554.0K | $-36M | $34M | $-5M | $-44M | $-179M | $10M | $3M | $30M | |
| Financing Cash Flow | $1M | $2M | $378.0K | $542.0K | $1M | $256.0K | $166M | $4M | $17M | $148M | $29M | $18M | $281M | $5M | · | · | |
| Net Change in Cash | $-6M | $-9M | $-553.0K | $389.0K | $-6M | $5M | $19M | $-56M | $-73M | $120M | $-26M | $-56M | $56M | $-15M | $45M | $-4M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-63M | · | · | $-47M | · | · | $-34M |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -21.7% | 0.30% | · | -29.4% | -25.4% | -42.2% | · | -99.8% | -7860.9% | -18465.1% | -29031.7% | -179141.4% | -190914.3% | -13450.5% | -38323.3% | -23313.0% | |
| Net Margin | -29.0% | -7.0% | · | -39.0% | -33.4% | -50.1% | · | -93.5% | -7639.8% | -18220.4% | -27320.1% | -169748.3% | -181533.3% | -13821.9% | -38516.4% | -24469.9% | |
| EBITDA Margin | -21.7% | 0.30% | · | -29.4% | -25.4% | -42.2% | · | -99.8% | -7860.9% | -18465.1% | -29031.7% | -179141.4% | -190914.3% | -13450.5% | -38323.3% | -23313.0% | |
| ROA | -3.1% | -0.66% | · | -3.6% | -3.3% | -3.8% | · | -6.2% | -15.6% | -12.2% | -13.9% | -15.1% | -12.2% | -17.8% | -11.5% | -13.2% | |
| ROE | -7.0% | -1.5% | · | -6.8% | -5.8% | -6.5% | · | -9.1% | -22.3% | -16.5% | -22.5% | -22.4% | -18.0% | -31.6% | -17.7% | -20.2% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.9 | 6.8 | · | 6.0 | 7.9 | 7.9 | · | 2.9 | 3.6 | 3.7 | 3.7 | 5.2 | 8.8 | 2.7 | 4.9 | 3.8 | |
| Quick Ratio | 1.6 | 1.5 | · | 1.3 | 1.8 | 1.8 | · | 0.6 | 1.1 | 1.5 | 0.3 | 0.8 | 2.6 | 0.7 | 1.6 | 0.7 | |
| Debt / Equity | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.5 | 0.4 | 0.5 | |
| LT Debt / Equity | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.4 | · | 0.0 | 0.1 | 0.0 | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 | 0.5 | |
| Interest Coverage | · | · | · | · | · | · | · | -9.3 | -20.9 | -16.4 | -23.0 | -25.9 | -20.9 | -22.0 | -17.7 | -19.4 |
Eficiencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Receivables Turnover | 1.3 | 1.4 | · | 1.5 | 2.6 | 2.5 | · | 2.0 | 2.0 | · | · | · | · | · | · | · |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $340.27 | $0.36 | · | $0.39 | $0.41 | $0.42 | · | $0.48 | $0.51 | $0.58 | $0.54 | $0.57 | $0.64 | $0.28 | $0.38 | $0.30 | |
| Revenue / Share | $85.70 | $77.44 | · | $0.07 | $0.07 | $0.06 | · | $0.04 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | · | |
| Cash Flow / Share | · | $-93.98 | · | · | · | $-0.07 | · | · | · | $-0.10 | · | · | $-0.09 | · | · | · | |
| Cash / Share | $97.50 | $0.11 | · | $0.12 | $0.12 | $0.13 | · | $0.10 | $0.19 | $0.32 | $0.06 | $0.11 | $0.22 | $0.16 | $0.20 | $0.10 | |
| EPS (TTM) | $-0.11 | $-0.11 | · | $-0.12 | $-0.13 | $-0.21 | · | $-0.31 | $-0.35 | $-0.34 | $-0.35 | $-0.37 | $-0.35 | $-0.35 | $-0.33 | $-0.35 |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | $1M | $1M | |
| Net Income TTM | $-68M | $-67M | · | $-80M | $-88M | $-139M | · | $-201M | $-220M | $-201M | $-175M | $-171M | $-150M | $-131M | $-117M | $-118M | |
| Market Cap | $822.4K | $955M | · | $875M | $899M | $1.01B | · | $2.74B | $2.55B | $1.95B | $1.15B | $1.68B | $1.10B | $892M | $585M | $440M | |
| Enterprise Value | $58M | $1.01B | · | $916M | $941M | $1.05B | · | $2.76B | $2.51B | $1.84B | $1.17B | $1.67B | $1.04B | $882M | $560M | $459M | |
| P/E | -11.6 | -13.5 | · | -11.4 | -10.8 | -7.6 | · | -14.6 | -12.1 | -9.7 | -6.1 | -8.7 | -6.2 | -6.7 | -4.7 | -3.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | 581.9 | 435.2 | 319.3 | |
| P/B | 0.0 | 4.2 | · | 3.5 | 3.5 | 3.8 | · | 9.4 | 8.3 | 5.7 | 4.0 | 5.6 | 3.4 | 8.2 | 4.1 | 4.5 | |
| P / Tangible Book | 0.0 | 4.2 | · | 3.5 | 3.5 | 3.8 | · | 9.4 | 8.3 | 5.7 | 4.0 | 5.6 | 3.4 | 8.2 | 4.1 | 4.5 | |
| P / Cash Flow | · | -15.2 | · | · | · | -21.1 | · | · | · | -31.3 | · | · | -23.8 | · | · | -13.0 | |
| EV / Revenue | · | · | · | · | · | · | · | · | · | · | · | · | · | 575.1 | 416.2 | 332.9 | |
| Earnings Yield | -8.6% | -7.4% | · | -8.8% | -9.2% | -13.2% | · | -6.8% | -8.2% | -10.3% | -16.5% | -11.5% | -16.1% | -15.0% | -21.3% | -25.7% |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | · | · | $237.0K | $596.0K | $1M |
| Margen Operativo % | · | · | -81832.9% | -23246.6% | -8183.7% |
| Beneficio neto | $-84M | $-175M | $-184M | $-142M | $-116M |
| EPS Diluido | $-0.13 | $-0.27 | $-0.32 | $-0.37 | $-0.35 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Deuda / Patrimonio | 0.5 | 0.4 | 0.3 | 0.6 | 0.4 |
| Ratio corriente | 4.7 | 5.6 | 3.2 | 2.4 | 4.1 |
| Ratio Rápido | 1.0 | 1.3 | 0.6 | 0.7 | 0.8 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | · | $-219M | $-169M | $-128M | $-96M |
Propietarios institucionales (13F) 275 declarantes · $662.3M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 37 (0 vs trimestre anterior) | 29 (-7 vs trimestre anterior) | 94 (+1 vs trimestre anterior) | 65 (+6 vs trimestre anterior) | -21.3M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| BlackRock, Inc. | $62 867 932 | 49 115 571 | 9,49% | Acciones |
| RA CAPITAL MANAGEMENT, L.P. | $54 796 481 | 42 809 751 | 8,27% | Acciones |
| Soleus Capital Management, L.P. | $54 795 084 | 42 808 659 | 8,27% | Acciones |
| VANGUARD GROUP INC | $47 072 479 | 35 660 969 | 7,11% | Acciones |
| STATE STREET CORP | $45 896 539 | 35 856 671 | 6,93% | Acciones |
| CITADEL ADVISORS LLC | $37 169 828 | 29 038 928 | 5,61% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $34 880 275 | 27 250 215 | 5,27% | Acciones |
| Clearbridge Investments, LLC | $25 150 531 | 19 648 853 | 3,80% | Acciones |
| Eversept Partners, LP | $23 958 300 | 18 717 422 | 3,62% | Acciones |
| GOLDMAN SACHS GROUP INC | $21 290 712 | 16 633 368 | 3,21% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $18 635 455 | 14 555 954 | 2,81% | Acciones |
| MORGAN STANLEY | $16 570 152 | 12 945 431 | 2,50% | Acciones |
| Nantahala Capital Management, LLC | $15 648 000 | 12 225 000 | 2,36% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $13 840 125 | 10 812 598 | 2,09% | Acciones |
| Vivo Capital, LLC | $11 099 900 | 8 671 797 | 1,68% | Acciones |
| MILLENNIUM MANAGEMENT LLC | $10 383 702 | 8 112 267 | 1,57% | Acciones |
| Kynam Capital Management, LP | $8 750 487 | 6 836 318 | 1,32% | Acciones |
| Candriam S.C.A. | $7 147 270 | 5 589 182 | 1,08% | Acciones |
| FMR LLC | $7 043 593 | 5 502 807 | 1,06% | Acciones |
| Pale Fire Capital SE | $6 793 221 | 5 307 204 | 1,03% | Acciones |
| NORTHERN TRUST CORP | $6 441 232 | 5 032 212 | 0,97% | Acciones |
| UBS Group AG | $6 267 002 | 4 896 096 | 0,95% | Acciones |
| RENAISSANCE TECHNOLOGIES LLC | $5 861 120 | 4 579 000 | 0,88% | Acciones |
| SEGALL BRYANT & HAMILL, LLC | $5 741 509 | 4 485 554 | 0,87% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $5 514 257 | 4 308 013 | 0,83% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $5 484 367 | 4 284 662 | 0,83% | Acciones |
| TORONTO DOMINION BANK | $5 420 800 | 4 235 000 | 0,82% | Acciones |
| Point72 Asset Management, L.P. | $5 177 857 | 4 045 201 | 0,78% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $5 073 361 | 3 963 563 | 0,77% | Acciones |
| BANK OF AMERICA CORP /DE/ | $4 523 820 | 3 534 234 | 0,68% | Acciones |
| DEUTSCHE BANK AG\ | $4 403 170 | 3 439 976 | 0,66% | Acciones |
| Qube Research & Technologies Ltd | $4 302 828 | 3 361 584 | 0,65% | Acciones |
| PANAGORA ASSET MANAGEMENT INC | $3 762 520 | 2 939 469 | 0,57% | Acciones |
| JANUS HENDERSON GROUP PLC | $3 303 915 | 2 218 196 | 0,50% | Acciones |
| ExodusPoint Capital Management, LP | $3 233 466 | 2 526 145 | 0,49% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $3 093 044 | 2 416 441 | 0,47% | Acciones |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $2 982 400 | 2 330 000 | 0,45% | Acciones |
| NAN FUNG TRINITY (HK) LTD | $2 846 144 | 2 223 550 | 0,43% | Acciones |
| Bank of New York Mellon Corp | $2 071 354 | 1 618 246 | 0,31% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 980 466 | 1 547 239 | 0,30% | Acciones |
| Nuveen, LLC | $1 979 489 | 1 546 476 | 0,30% | Acciones |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $1 893 811 | 1 271 014 | 0,29% | Acciones |
| World Investment Advisors | $1 540 331 | 1 033 779 | 0,23% | Acciones |
| MOORE CAPITAL MANAGEMENT, LP | $1 525 684 | 1 191 941 | 0,23% | Acciones |
| Invesco Ltd. | $1 504 266 | 1 175 208 | 0,23% | Acciones |
| Kodai Capital Management LP | $1 420 015 | 893 091 | 0,21% | Acciones |
| Seven Fleet Capital Management LP | $1 353 252 | 1 057 228 | 0,20% | Acciones |
| Virtus Investment Advisers, LLC | $1 294 337 | 1 011 201 | 0,20% | Acciones |
| Voleon Capital Management LP | $1 286 385 | 1 004 988 | 0,19% | Acciones |
| Swiss National Bank | $1 233 920 | 964 000 | 0,19% | Acciones |
Activistas y propietarios del %+ 5 3 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| 3 de febrero de 2023 | · | Presentación inicial | · | SEC | |
| Growth Equity Opportunities 17, LLC, New Enterprise Associates 17, L.P., NEA Partners 17, L.P., NEA 17 GP, LLC, Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Liza Landsman, Mohamad H. Makhzoumi, Joshua Makower, Edward T. Mathers, Scott D. Sandell, Peter W. Sonsini, Paul Walker, Rick Yang | 4 de junio de 2020 | · | Presentación inicial | Inversión pasiva | SEC |
| G ERON C ORPORATION ×3 presentaciones | 19 de agosto de 2014 | · | Presentación inicial | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 49 insiders · 28 directivos · 23 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Harout Semerjian | President and CEO | 7 de agosto de 2025 A | · | 0 | 0 | $0 |
| John A Scarlett | Chairman, President and CEO | 27 de febrero de 2025 P | 12 500 | 0 | 0 | $0 |
| David Greenwood | President, Interim CEO, CFO | 14 de junio de 2011 S | 754 031 | 0 | 0 | $0 |
| Thomas Okarma | President and CEO | 9 de julio de 2010 A | 774 560 | 0 | 0 | $0 |
| Michelle Robertson | EVP, CHIEF FINANCIAL OFFICER | 18 de febrero de 2026 M | 17 645 | 0 | 1 | $-19 119 |
| Olivia Kyusuk Bloom | EVP, Chief Financial Officer | 15 de agosto de 2023 A | 74 588 | 0 | 0 | $0 |
| Graham K Cooper | EVP, Bus Dev & CFO | 17 de mayo de 2012 A | · | 0 | 0 | $0 |
| Alan Colowick | President, Oncology | 2 de enero de 2008 I | 3 028 | 0 | 0 | $0 |
| Andrew J Grethlein | EVP, Chief Operating Officer | 18 de febrero de 2025 A | 0 | 0 | 0 | $0 |
| Timothy Williams | EVP and Chief Legal Officer | 13 de abril de 2026 A | · | 0 | 0 | $0 |
| Joseph Eid | EVP, R&D; Chief Medical Office | 17 de febrero de 2026 A | · | 0 | 0 | $0 |
| Ahmed Elnawawi | EVP, Chief Commercial Officer | 20 de octubre de 2025 A | · | 0 | 0 | $0 |
| James Ziegler | EVP, Chief Commercial Officer | 27 de febrero de 2025 P | 100 000 | 0 | 0 | $0 |
| Scott Alan Samuels | EVP, Chief Legal Officer | 27 de febrero de 2025 P | 26 682 | 0 | 0 | $0 |
| Faye Feller | EVP, Chief Medical Officer | 10 de junio de 2024 M | 0 | 0 | 0 | $0 |
| Anil Kapur | EVP, Corp Strategy & CCO | 10 de junio de 2024 M | 0 | 0 | 0 | $0 |
| Aleksandra Rizo | EVP, Chief Medical Officer | 16 de febrero de 2022 A | · | 0 | 0 | $0 |
| Stephen Rosenfield | EVP, Chief Legal Off & Sec | 16 de febrero de 2022 A | 0 | 0 | 0 | $0 |
| Melissa Kelly Behrs | EVP, Chief Business Officer | 2 de febrero de 2021 A | 0 | 0 | 0 | $0 |
| Craig C Parker | EVP, Corp Dev & Sci Affairs | 10 de febrero de 2014 A | · | 0 | 0 | $0 |
| Stephen Michael Kelsey | EVP, R&D, Chief Med Officer | 3 de mayo de 2013 D | 62 272 | 0 | 0 | $0 |
| David Earp | SVP, Corp Transactions | 30 de mayo de 2012 S | 467 406 | 0 | 0 | $0 |
| Katharine E. Spink | SVP Alliance Mgmt & Operations | 14 de junio de 2011 S | 328 561 | 0 | 0 | $0 |
| Jane Lebkowski | SVP, Chief Scientific Officer | 14 de junio de 2011 S | 568 154 | 0 | 0 | $0 |
| Melanie I Nallicheri | SVP Corp Dev | 20 de mayo de 2011 A | 195 000 | 0 | 0 | $0 |
| Fabio M Benedetti | SVP, Chief Med Off, Oncology | 29 de mayo de 2009 A | 80 560 | 0 | 0 | $0 |
| Calvin Harley | VP, CSO Telomerase Tech | 29 de mayo de 2009 A | 134 036 | 0 | 0 | $0 |
| William Stempel | VP and General Counsel | 27 de mayo de 2004 A | 6 521 | 0 | 0 | $0 |
| Robert J. Spiegel | Consejero | 30 de septiembre de 2026 A | 212 161 | 0 | 0 | $0 |
| John F Mcdonald | Consejero | 20 de mayo de 2026 A | · | 0 | 0 | $0 |
| Elizabeth G. O'Farrell | Consejero | 20 de mayo de 2026 A | 26 220 | 0 | 0 | $0 |
| Dawn Carter Bir | Consejero | 20 de mayo de 2026 A | · | 0 | 0 | $0 |
| Susan Molineaux | Consejero | 20 de mayo de 2026 A | 130 527 | 0 | 0 | $0 |
| Constantine Chinoporos | Consejero | 25 de marzo de 2026 A | · | 0 | 0 | $0 |
| Patricia S Andrews | Consejero | 25 de marzo de 2026 A | · | 0 | 0 | $0 |
| Gaurav Aggarwal | Consejero | 21 de mayo de 2025 A | 1 970 | 0 | 0 | $0 |
| Bryan V Lawlis | Consejero | 21 de mayo de 2025 A | 13 300 | 0 | 0 | $0 |
| Karin Eastham | Consejero | 13 de enero de 2023 M | 109 047 | 0 | 0 | $0 |
| Daniel Bradbury | Consejero | 29 de marzo de 2019 A | 51 323 | 0 | 0 | $0 |
| Hoyoung Huh | Consejero | 15 de mayo de 2018 A | 154 301 | 0 | 0 | $0 |
| Thomas Hofstaetter | Consejero | 18 de marzo de 2015 M | 26 564 | 0 | 0 | $0 |
| Thomas Kiley | Consejero | 22 de mayo de 2013 D | 171 911 | 0 | 0 | $0 |
| Edward V Fritzky | Consejero | 22 de mayo de 2013 D | 186 511 | 0 | 0 | $0 |
| Alexander E Barkas | Consejero | 20 de mayo de 2011 A | 353 122 | 0 | 0 | $0 |
| Charles J Homcy | Consejero | 11 de mayo de 2011 A | 62 751 | 0 | 0 | $0 |
| ZENNER PATRICK J | Consejero | 19 de mayo de 2010 A | 73 710 | 0 | 0 | $0 |
| John Peter Walker | Consejero | 30 de enero de 2009 M | 39 119 | 0 | 0 | $0 |
| Robert B Stein | Consejero | 23 de septiembre de 2003 M | 0 | 0 | 0 | $0 |
| MERIX BIOSCIENCE INC | Propietario del 10% | 16 de agosto de 2004 S | 4 541 100 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 24 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,54% | 1 180 129 NS | 31 de julio de 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,42% | 80 446 SH | 2 de octubre de 2026 | Diario |
| LABU · Direxion Shares ETF Trust | 0,19% | 741 331 NS | 31 de julio de 2026 | N-PORT |
| ESSC · Strategy Shares | 0,13% | 35 108 NS | 31 de julio de 2026 | N-PORT |
| IBB · iShares Trust | 0,06% | 4 783 606 SH | 11 de septiembre de 2026 | Diario |
| PWS · Pacer Funds Trust | 0,05% | 10 128 NS | 31 de julio de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,05% | 45 101 SH | 2 de octubre de 2026 | Diario |
| IWO · iShares Trust | 0,05% | 5 238 232 SH | 11 de septiembre de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 599 922 SH | 19 de agosto de 2026 | Diario |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,04% | 774 301 SH | 2 de octubre de 2026 | Diario |
| IWM · iShares Trust | 0,03% | 14 214 009 SH | 11 de septiembre de 2026 | Diario |
| RSSL · Global X Funds | 0,02% | 267 254 NS | 31 de julio de 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3 218 859 SH | 19 de agosto de 2026 | Diario |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 6 164 114 SH | 19 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,01% | 1 437 897 SH | 19 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 237 415 NS | 31 de julio de 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 34 308 SH | 10 de septiembre de 2026 | Diario |
| IWV · iShares Trust | 0,00% | 169 800 SH | 10 de septiembre de 2026 | Diario |
| ITOT · iShares Trust | 0,00% | 725 966 SH | 11 de septiembre de 2026 | Diario |
| TILT · FlexShares Trust | 0,00% | 3 634 NS | 31 de julio de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 20 449 234 SH | 19 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 41 165 SH | 19 de agosto de 2026 | Diario |
| ISCB · iShares Trust | · | 21 772 SH | 11 de septiembre de 2026 | Diario |
| ISCV · iShares Trust | · | 107 848 SH | 11 de septiembre de 2026 | Diario |
GERN Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
Precio objetivo a 12 meses
4 analistas · 2026-09-28Objetivo medio $4.25 +254,2%
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| GERN | $845M | -10.2 | -60.2% | · | -34.4% | · |
| ARDX | $1.42B | -22.4 | 22.1% | -15.1% | -40.2% | · |
| ANNX | $750M | -3.7 | · | · | -100.7% | · |
| AVTX | $336M | -3.1 | -86.6% | -132642.4% | -83.4% | · |
| CADL | $310M | -7.8 | · | · | -53.7% | · |
| DSGN | $567M | -7.7 | · | · | -32.8% | · |
| GYRE | $645M | 353.0 | 10.2% | 8.5% | 11.7% | · |
| FDMT | $432M | -3.1 | 230194.6% | -164.4% | -30.2% | · |
| ACHV | · | -4.0 | · | · | · | · |
| SLDB | $445M | -2.8 | · | · | -79.5% | · |
Últimas noticias Noticias recientes que mencionan a esta empresa
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.